CDH1 and cancer: The hypomethylating agent 5-Aza-2′-deoxycytidine (5-Azacytidine) is well approved as a DNA methyltransferase inhibitor and hypermethylation of the CpG island in the E-cadherin promoter plays an important role in cancer invasion and dissemination [40, 41].